Costs of treating infections caused by methicillin-resistant staphylococci and vancomycin-resistant enterococci.
about
In vivo activity of ceftobiprole in murine skin infections due to Staphylococcus aureus and Pseudomonas aeruginosa.Photodynamic effects of novel XF porphyrin derivatives on prokaryotic and eukaryotic cells.Influence of First-Line Antibiotics on the Antibacterial Activities of Acetone Stem Bark Extract of Acacia mearnsii De Wild. against Drug-Resistant Bacterial Isolates.Efficacy of linezolid in treatment of experimental endocarditis caused by methicillin-resistant Staphylococcus aureus.Activity of novispirin G10 against Pseudomonas aeruginosa in vitro and in infected burns.Using interrupted time series analysis to assess associations of fluoroquinolone formulary changes with susceptibility of gram-negative pathogens and isolation rates of methicillin-resistant Staphylococcus aureusAntimicrobial growth promoters used in animal feed: effects of less well known antibiotics on gram-positive bacteria.Comparison of culture screening methods for detection of nasal carriage of methicillin-resistant Staphylococcus aureus: a prospective study comparing 32 methodsA profile and spectrum of four cases of methicillin-resistant Staphylococcus aureus in a burns intensive care unit.Aromatic Compound-Dependent Staphylococcus aureus Is Safe in a Nasal Colonization Leukopenic Murine Model.Nosocomial bacterial infections in Intensive Care Units. I: Organisms and mechanisms of antibiotic resistance.Patterns and determinants of inappropriate antibiotic use in injection drug usersLinezolid: a promising option in the treatment of Gram-positives.Monitoring bioluminescent Staphylococcus aureus infections in living mice using a novel luxABCDE construct.Staphylococcus aureus osteomyelitis in Hawaii.Antimicrobial use and microbiological testing in district general hospital ICUs of the Veneto region of north-east Italy.Use of cefoxitin-based selective broth for improved detection of methicillin-resistant Staphylococcus aureusA case of methicillin-resistant Staphylococcus aureus infection following bile duct stenting.Impact of linezolid on economic outcomes and determinants of cost in a clinical trial evaluating patients with MRSA complicated skin and soft-tissue infections.Risk factors for colonization with vancomycin-resistant enterococci in a Melbourne hospital.Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections.Clinical experience of quinupristin-dalfopristin for the treatment of antimicrobial-resistant gram-positive infections.Risk of methicillin-resistant Staphylococcus aureus infection after previous infection or colonization.Nosocomial infections due to methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococcus: relationships with antibiotic use and cost drivers.Implant stability in the treatment of MRSA bone implant infections with linezolid versus vancomycin in a rabbit model.Clinical and economic analysis of methicillin-susceptible and -resistant Staphylococcus aureus infections.In vitro activity of linezolid and other antibiotics against Gram-positive bacteria from the major teaching hospitals in Kuwait.Efficacy and safety of linezolid compared with other treatments for skin and soft-tissue infections: a meta-analysis.
P2860
Q33559139-09A95132-5036-4972-90AC-7B8C6318BF7EQ33722039-9772700D-2AD0-456F-A6B8-CDDD1B4D0A03Q33914695-4A8A43A2-E3B6-4BC3-98AA-25934C2D1A36Q33982746-B9450082-A751-48BD-9E16-1F3865E4A7E3Q34108244-5C9C77FF-6F3A-4F09-8971-6B74C7B18A59Q34680578-A930FC8E-B0C0-4E8C-83A3-50E2FBAA46E7Q34927077-6637A21C-007E-4A23-B5AD-EEEBDA50D76CQ35156684-B94BAEE2-B515-45E7-9721-DACCFD6B99C8Q35279347-0271EE07-6F53-4715-B7CA-99C685113F82Q36167419-354EF145-878D-4B57-8166-F3043BBF35ACQ36237707-439FAEDE-D804-4A73-9C49-B681693DA84DQ37067751-C215C495-6726-42A8-9CA4-49F8B727192AQ39044932-DB318719-C2E2-4225-BCCD-3E465ADE78D2Q39516464-2D3B794E-A12D-4A6A-8AE3-89193804C167Q40367411-01621D64-1B7A-417A-8EC4-609A1FD86B04Q40701338-805B6CEA-17DE-4E73-8CE2-9C9AE37A3A17Q41882886-C4091372-AA3F-4959-AF2D-AB0EF1C4679EQ41979759-1989F2C9-2C61-4098-8B48-7CBECD0F96C3Q42686505-7F79A150-B360-400D-81DE-5C3223A16BDBQ43844989-F453FA4C-D1AE-4303-871E-B94009E1D8FAQ43996924-A9DE9C45-C82B-4928-92BF-5B507793FCE7Q43999843-9396596E-B915-420E-A209-8FA94D6D0062Q44285693-5E588E3F-BBA2-4EB4-8189-315A8BFDD771Q44602337-3BB3E7F6-D6C6-4064-A4DA-09E4E8CCFC46Q44769624-D504FF5E-DF2C-4392-8A29-265082C5E983Q44987609-E84B46A2-55CA-4FDB-AC6D-AF7A3587A361Q46908680-2D14B306-5DB1-43CA-8025-1224623C520DQ47327608-18C8267E-E16B-4EC3-93D0-0904B04C1A0D
P2860
Costs of treating infections caused by methicillin-resistant staphylococci and vancomycin-resistant enterococci.
description
1999 nî lūn-bûn
@nan
1999 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Costs of treating infections c ...... comycin-resistant enterococci.
@ast
Costs of treating infections c ...... comycin-resistant enterococci.
@en
type
label
Costs of treating infections c ...... comycin-resistant enterococci.
@ast
Costs of treating infections c ...... comycin-resistant enterococci.
@en
prefLabel
Costs of treating infections c ...... comycin-resistant enterococci.
@ast
Costs of treating infections c ...... comycin-resistant enterococci.
@en
P356
P1476
Costs of treating infections c ...... comycin-resistant enterococci.
@en
P2093
P356
10.1093/JAC/44.SUPPL_1.31
P407
P478
44 Suppl A
P577
1999-09-01T00:00:00Z